Table of contents
- Trial overview
- Who can participate
- Study design and phases
- What is being measured
- Treatment and comparison plan
- What the trial means for patients
Trial overview
The listed study is an interventional Phase 1/2 trial of AAV9-CTNT-COBAG3 in adults with BAG3-associated dilated cardiomyopathy.[1] It is authorised and plans to enroll 18 participants.[1]
The trial title names ALXN2350, while the provided data also lists AAV9 as an intravenous intervention in the study.[1] The study is focused on an inherited heart condition linked to a BAG3 mutation.[1]
Who can participate
The target population is adult participants with BAG3-associated dilated cardiomyopathy.[1] No other age groups or conditions are described in the source data.[1]
This means the study is not described as a general heart failure trial, but as a trial for a specific genetic form of dilated cardiomyopathy.[1]
Study design and phases
This is an interventional study, which means the research team gives a treatment and then measures what happens.[1] The study is in Phase 1/2, so it is early in development and is designed to first study safety and then look for possible benefit.[1]
According to the brief summary, Part A is designed to determine safety and tolerability after a single intravenous infusion of ALXN2350 in participants with BAG3-associated DCM.[1] Part B is designed to evaluate clinical impact, meaning whether there are signs that the treatment may help, compared with an external control.[1]
What is being measured
The primary outcome for Part A is the incidence and severity of treatment-emergent adverse events and serious adverse events.[1] In simple terms, the study checks how often health problems happen after treatment and how severe they are.[1]
The trial also records clinically significant safety findings from physical examinations, vital sign measurements, clinical laboratory assessments, and ECG results.[1] These tests help researchers see whether the treatment affects the body or heart in important ways.[1]
Treatment and comparison plan
The study description says participants receive a single intravenous infusion of ALXN2350 in Part A.[1] The intervention list also includes AAV9 given by intravenous use, along with several oral medicines such as Rapamune, prednisone, and co-trimoxazole.[1]
For Part B, the trial compares clinical impact against an external control.[1] An external control means the results are compared with data from another group outside the treatment arm rather than from people in the same study who receive a different treatment.[1]
What the trial means for patients
This trial is aimed at a small group of adults with a rare inherited heart disease.[1] Because it is early-stage, the main question is whether the study treatment can be given safely and whether there are early signs of benefit.[1]
For patients, the most important point is that the study is not yet a confirmed treatment standard; it is research designed to learn more about AAV9-CTNT-COBAG3 in BAG3-associated dilated cardiomyopathy.[1]
